RU2018145067A - Питательные композиции для защиты сердца у животных-компаньонов - Google Patents
Питательные композиции для защиты сердца у животных-компаньонов Download PDFInfo
- Publication number
- RU2018145067A RU2018145067A RU2018145067A RU2018145067A RU2018145067A RU 2018145067 A RU2018145067 A RU 2018145067A RU 2018145067 A RU2018145067 A RU 2018145067A RU 2018145067 A RU2018145067 A RU 2018145067A RU 2018145067 A RU2018145067 A RU 2018145067A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- companion animal
- group
- animal
- triglycerides
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 23
- 241001465754 Metazoa Species 0.000 title claims 20
- 235000016709 nutrition Nutrition 0.000 title 1
- 238000000034 method Methods 0.000 claims 22
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 6
- 229940057917 medium chain triglycerides Drugs 0.000 claims 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 229960003646 lysine Drugs 0.000 claims 4
- 239000011777 magnesium Substances 0.000 claims 4
- 229910052749 magnesium Inorganic materials 0.000 claims 4
- 235000001055 magnesium Nutrition 0.000 claims 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 4
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 229960003080 taurine Drugs 0.000 claims 4
- 208000011682 Mitral valve disease Diseases 0.000 claims 3
- 229930003427 Vitamin E Natural products 0.000 claims 3
- 230000003412 degenerative effect Effects 0.000 claims 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 3
- 229940091250 magnesium supplement Drugs 0.000 claims 3
- 239000006014 omega-3 oil Substances 0.000 claims 3
- 229960005349 sulfur Drugs 0.000 claims 3
- 150000003626 triacylglycerols Chemical class 0.000 claims 3
- 235000019165 vitamin E Nutrition 0.000 claims 3
- 229940046009 vitamin E Drugs 0.000 claims 3
- 239000011709 vitamin E Substances 0.000 claims 3
- 241000282465 Canis Species 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 2
- 230000005189 cardiac health Effects 0.000 claims 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- 230000003647 oxidation Effects 0.000 claims 2
- 238000007254 oxidation reaction Methods 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- 208000035211 Heart Murmurs Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 1
- 206010027727 Mitral valve incompetence Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 208000003443 Unconsciousness Diseases 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229960004203 carnitine Drugs 0.000 claims 1
- 230000001010 compromised effect Effects 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims 1
- 230000037149 energy metabolism Effects 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 230000034659 glycolysis Effects 0.000 claims 1
- 150000004668 long chain fatty acids Chemical class 0.000 claims 1
- 150000004667 medium chain fatty acids Chemical class 0.000 claims 1
- 229960004452 methionine Drugs 0.000 claims 1
- 230000001452 natriuretic effect Effects 0.000 claims 1
- 229960002446 octanoic acid Drugs 0.000 claims 1
- 230000037081 physical activity Effects 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/24—Compounds of alkaline earth metals, e.g. magnesium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/48—Moist feed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (22)
1. Способ поддержания или улучшения состояния здоровья сердца у животного-компаньона, включающий пероральное введение животному-компаньону композиции, содержащей терапевтически эффективное количество триглицеридов со средней длиной цепи.
2. Способ по п. 1, в котором композиция дополнительно содержит компонент, выбранный из группы, состоящей из омега-3 жирной кислоты, витамина E, магния, таурина, лизина, серосодержащей аминокислоты и их смесей.
3. Способ по п. 2, в котором омега-3 жирная кислота выбрана из группы, состоящей из эйкозапентаеновой кислоты (EPA), докозагексаеновой кислоты (DHA) и их смесей.
4. Способ по п. 2, в котором серосодержащая аминокислота выбрана из группы, состоящей из метионина, цистеина, гомоцистеина, таурина и их смесей.
5. Способ по п. 1, в котором композиция представляет собой полноценный и сбалансированный по питательной ценности корм для домашних животных.
6. Способ по п. 1, в котором триглицериды со средней длиной цепи составляют от около 0,5 мас.% до около 60 мас.% композиции.
7. Способ по п. 1, в котором триглицериды со средней длиной цепи включают в себя среднецепочечную жирную кислоту, выбранную из группы, состоящей из каприловой кислоты, каприновой кислоты и их смеси.
8. Способ по п. 1, в котором композиция дополнительно содержит компонент, выбранный из группы, состоящей из карнитина, лизина и метионина, глутатиона и их смеси.
9. Способ по п. 1, в котором композиция имеет характеристику, выбранную из группы, состоящей из (i) соотношения количеств калия и натрия от около 4 : 1 до около 1 : 1, (ii) содержания магния в количестве от около 0,08 мас.% до около 0,25 мас.%, (iii) содержания белка в количестве по меньшей мере 20 мас.% и (iv) их комбинаций.
10. Способ по п. 1, в котором композицию вводят животному-компаньону ежедневно в течение по меньшей мере одной недели.
11. Способ по п. 1, в котором композицию вводят в количестве, обеспечивающем от около 0,001 г до около 50,0 г триглицеридов со средней длиной цепи (ТСЦ) на кг массы тела животного-компаньона в сутки.
12. Способ по п. 1, в котором поддержание или улучшение состояния здоровья сердца приводит к лечению дегенеративного заболевания митрального клапана (DMVD).
13. Способ по п. 1, в котором животное-компаньон представляет собой животное из семейства собачьих.
14. Способ лечения дегенеративного заболевания митрального клапана (DMVD) у нуждающегося в этом животного-компаньона, включающий пероральное введение животному-компаньону композиции, содержащей терапевтически эффективное количество триглицеридов со средней длиной цепи.
15. Способ по п. 14, в котором триглицериды со средней длиной цепи составляют от около 0,5 мас.% до около 60 мас.% композиции.
16. Способ по п. 14, в котором композиция дополнительно содержит компонент, выбранный из группы, состоящей из омега-3 жирной кислоты, витамина E, магния, таурина, лизина, серосодержащей аминокислоты и их смесей.
17. Способ по п. 14, в котором животное-компаньон представляет собой животное из семейства собачьих.
18. Способ профилактики дегенеративного заболевания митрального клапана (DMVD) у подверженного риску животного-компаньона, включающий пероральное введение животному-компаньону композиции, содержащей профилактическую дозу триглицеридов со средней длиной цепи.
19. Способ по п. 18, в котором триглицериды со средней длиной цепи составляют от около 0,5 мас.% до около 60 мас.% композиции.
20. Способ по п. 18, в котором композиция дополнительно содержит компонент, выбранный из группы, состоящей из омега-3 жирной кислоты, витамина E, магния, таурина, лизина, серосодержащей аминокислоты и их смесей.
21. Способ по п. 18, включающий идентификацию животного-компаньона как подверженного риску DMVD перед введением композиции животному-компаньону.
22. Способ по п. 21, в котором идентификация включает стадию, выбранную из группы, состоящей из (i) измерения концентрации про-натрийуретического N-концевого пептида В-типа у животного-компаньона, (ii) обнаружения увеличения сердца у животного-компаньона, (iii) обнаружения шума в сердце у животного-компаньона, (iv) обнаружения в анамнезе у животного-компаньона одного или более из кашля, непереносимости физической нагрузки, сниженного аппетита, затруднения дыхания или временной потери сознания, вызванной падением артериального давления, (v) идентификации принадлежности животного компаньона к мелкой породе, (vi) обнаружения митральной регургитации, (vii) измерения изменений путей передачи сигнала серотонина, трансформирующего фактора роста бета или оксида азота, (viii) измерения изменений энергетического метаболизма, включая нарушение бета-окисления длинноцепочечных жирных кислот, нарушения альфа-окисления жирных кислот с разветвленной цепью, нарушения кетолиза или усиления потребления глюкозы и гликолиза и (ix) их комбинаций.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662339436P | 2016-05-20 | 2016-05-20 | |
US62/339,436 | 2016-05-20 | ||
PCT/IB2017/052981 WO2017199223A1 (en) | 2016-05-20 | 2017-05-19 | Nutritional compositions for cardciac protection in companion animals |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2018145067A true RU2018145067A (ru) | 2020-06-22 |
RU2018145067A3 RU2018145067A3 (ru) | 2020-09-11 |
RU2744134C2 RU2744134C2 (ru) | 2021-03-03 |
Family
ID=58993169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018145067A RU2744134C2 (ru) | 2016-05-20 | 2017-05-19 | Питательные композиции для защиты сердца у животных-компаньонов |
Country Status (15)
Country | Link |
---|---|
US (1) | US20170332686A1 (ru) |
EP (1) | EP3458046B1 (ru) |
JP (1) | JP6920343B2 (ru) |
CN (1) | CN109069465B (ru) |
AU (1) | AU2017267615B2 (ru) |
BR (1) | BR112018072064B8 (ru) |
CA (1) | CA3021169A1 (ru) |
CL (1) | CL2018003075A1 (ru) |
ES (1) | ES2851923T3 (ru) |
HU (1) | HUE053622T2 (ru) |
MX (1) | MX2018014083A (ru) |
NZ (1) | NZ746681A (ru) |
PL (1) | PL3458046T3 (ru) |
RU (1) | RU2744134C2 (ru) |
WO (1) | WO2017199223A1 (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11813238B2 (en) | 2017-05-29 | 2023-11-14 | Societe Des Produits Nestle S.A. | Medium chain fatty acids for use in the prevention or treatment of cardiac enlargement and/or valvular heart disease |
MX2020004739A (es) | 2017-11-17 | 2020-09-21 | Hills Pet Nutrition Inc | Composiciones que comprenden acidos grasos de cadena media y poliinsaturados omega-3. |
WO2019234628A1 (en) * | 2018-06-07 | 2019-12-12 | Société des Produits Nestlé S.A. | Methods and compositions for increasing ketone bodies in animals |
EP4316477A1 (en) * | 2018-08-22 | 2024-02-07 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Methods for treating cardiac valve disease |
CN109007397A (zh) * | 2018-08-23 | 2018-12-18 | 广东仁源生物科技有限公司 | 一种可以改善小鼠心脏形态结构与功能的饲料组合物及其制备方法 |
MX2021006183A (es) * | 2018-12-27 | 2021-06-18 | Nestle Sa | Composiciones y metodos para diagnosticar y tratar la enfermedad degenerativa de la valvula mitral en un canino. |
KR20210120091A (ko) | 2019-02-01 | 2021-10-06 | 마아즈, 인코오포레이티드 | 고양잇과 동물용 사료 조성물 |
EP3941455A1 (en) * | 2019-03-22 | 2022-01-26 | Société des Produits Nestlé S.A. | Methods using administration of medium chain triglycerides (mct) prior to a meal to increase ketone production from the mcts |
CN113840536A (zh) * | 2019-05-31 | 2021-12-24 | 雀巢产品有限公司 | 用于在动物中提供健康有益效果的基于mct的营养共混物 |
GB201908111D0 (en) * | 2019-06-06 | 2019-07-24 | Mars Inc | Modulation of the oral microbiota |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4920098A (en) * | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
AU784852B2 (en) * | 2001-08-10 | 2006-07-06 | Mars, Incorporated | Canine support diet |
US7514107B2 (en) * | 2002-03-21 | 2009-04-07 | Mars, Incorporated | Treatment of diseases involving defective gap junctional communication |
JP2005047851A (ja) * | 2003-07-29 | 2005-02-24 | Nisshin Pharma Inc | ユビデカレノン含有組成物 |
BRPI0413645B1 (pt) * | 2003-09-05 | 2014-08-05 | Hills Pet Nutrition Inc | Composição para o consumo animal, processo para a produção da mesma |
BRPI0514794A (pt) * | 2004-08-30 | 2008-06-24 | Hills Pet Nutrition Inc | métodos para fornecer nutrição para um animal, para promover o bem estar de um animal, para prescrever uma dieta de bem estar para um animal, e para construir uma matriz de composições alimentìcias para um espécie animal, ração para um animal, sistema auxiliado por computador, kit, e, meio para comunicar informação sobre ou instruções para misturar e administrar uma ração |
US7595079B2 (en) * | 2005-07-08 | 2009-09-29 | Bomac Vets Plus, Inc. | Nutritional conjunctive support therapy for recovery in animals following stress or illness |
AU2006326040B2 (en) * | 2005-12-15 | 2012-02-09 | Société des Produits Nestlé S.A. | Compositions and methods for preserving brain function |
EP2044930A1 (en) * | 2007-10-01 | 2009-04-08 | Nestec S.A. | Composition for controlling lipase catalyzed reactions |
CA2819676C (en) * | 2007-12-21 | 2016-08-02 | Hill's Pet Nutrition, Inc. | Pet food composition |
JP5513852B2 (ja) * | 2009-11-05 | 2014-06-04 | 花王株式会社 | 犬の僧帽弁閉鎖不全症及び/又は三叉弁閉鎖不全の発症リスク低減方法 |
WO2012037328A2 (en) * | 2010-09-17 | 2012-03-22 | Maine Natural Health, Inc. | Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof |
BR112013026706A2 (pt) * | 2011-04-18 | 2016-12-27 | Nestec Sa | composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico |
FR2982460B1 (fr) * | 2011-11-14 | 2016-08-05 | Virbac Sa | Produits pour administration orale comprenant des extraits de grenade punica granatum, destines a un animal de compagnie, et ses applications |
US20140171415A1 (en) * | 2012-12-14 | 2014-06-19 | Boehringer Ingelheim Vetmedica Gmbh | Funny current (if) inhibitors for use in a method of treating and preventing heart disease in canine |
JP2014210761A (ja) * | 2013-04-05 | 2014-11-13 | 株式会社シバヤギ | 抗イヌn末端プロ心房性ナトリウム利尿ペプチド抗体ならびにそれを用いた免疫学的測定方法、および免疫学的測定用キット |
WO2014196957A1 (en) * | 2013-06-03 | 2014-12-11 | Nestec Sa | Methods for diagnosing chronic valvular disease |
EP3019024B1 (en) * | 2013-06-28 | 2017-02-01 | Nestec S.A. | Compositions and methods for enhancing exercise performance |
-
2017
- 2017-05-19 MX MX2018014083A patent/MX2018014083A/es unknown
- 2017-05-19 CN CN201780029510.3A patent/CN109069465B/zh active Active
- 2017-05-19 HU HUE17727386A patent/HUE053622T2/hu unknown
- 2017-05-19 PL PL17727386T patent/PL3458046T3/pl unknown
- 2017-05-19 AU AU2017267615A patent/AU2017267615B2/en active Active
- 2017-05-19 EP EP17727386.9A patent/EP3458046B1/en active Active
- 2017-05-19 US US15/600,210 patent/US20170332686A1/en not_active Abandoned
- 2017-05-19 CA CA3021169A patent/CA3021169A1/en active Pending
- 2017-05-19 NZ NZ746681A patent/NZ746681A/en unknown
- 2017-05-19 RU RU2018145067A patent/RU2744134C2/ru active
- 2017-05-19 WO PCT/IB2017/052981 patent/WO2017199223A1/en unknown
- 2017-05-19 ES ES17727386T patent/ES2851923T3/es active Active
- 2017-05-19 JP JP2018554553A patent/JP6920343B2/ja active Active
- 2017-05-19 BR BR112018072064A patent/BR112018072064B8/pt active IP Right Grant
-
2018
- 2018-10-29 CL CL2018003075A patent/CL2018003075A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3458046A1 (en) | 2019-03-27 |
CN109069465B (zh) | 2021-08-17 |
NZ746681A (en) | 2022-07-01 |
PL3458046T3 (pl) | 2021-07-05 |
CA3021169A1 (en) | 2017-11-23 |
BR112018072064A2 (pt) | 2019-02-12 |
WO2017199223A1 (en) | 2017-11-23 |
EP3458046B1 (en) | 2021-01-13 |
CL2018003075A1 (es) | 2018-12-07 |
ES2851923T3 (es) | 2021-09-09 |
AU2017267615B2 (en) | 2022-03-17 |
BR112018072064B8 (pt) | 2022-08-23 |
AU2017267615A1 (en) | 2018-10-18 |
JP6920343B2 (ja) | 2021-08-18 |
CN109069465A (zh) | 2018-12-21 |
US20170332686A1 (en) | 2017-11-23 |
MX2018014083A (es) | 2019-04-04 |
RU2744134C2 (ru) | 2021-03-03 |
JP2019521646A (ja) | 2019-08-08 |
RU2018145067A3 (ru) | 2020-09-11 |
HUE053622T2 (hu) | 2021-07-28 |
BR112018072064B1 (pt) | 2022-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2018145067A (ru) | Питательные композиции для защиты сердца у животных-компаньонов | |
US20150132402A1 (en) | Dietary supplements for promotion of growth, repair, and maintenance of bone and joints | |
KR20180100455A (ko) | 영양 조성물 | |
JP5714227B2 (ja) | アンドログラホリドを有効成分とする抗疲労剤及び経口組成物 | |
JP2015510888A5 (ru) | ||
WO2011151632A1 (en) | Dietary formulations | |
JP2013515500A (ja) | 炎症性の病気の改善または予防のための、ショウガが含まれる組成物 | |
BR112015032572A2 (pt) | composições e métodos para melhorar o desempenho durante exercícios | |
Daidj et al. | Hepatoprotective and anti-obesity properties of sardine by-product oil in rats fed a high-fat diet | |
WO2012137953A1 (ja) | 動物用栄養組成物 | |
Ali et al. | Effect of injection with bee venom extract on productive performance and immune response of broiler chicks | |
JP6538043B2 (ja) | 腎機能を向上させるための方法及び組成物 | |
CN110521872A (zh) | 一种赖氨酸膏及其在猫咪营养摄取中的应用 | |
TWI640314B (zh) | 戈氏副擬桿菌用於降低胰島素抗性及提升葡萄糖耐受性之用途 | |
JP2005312365A (ja) | リジン含有抗肥満または抗高脂血食品、飼料またはサプリメント | |
Klatz | The Official Anti-Aging Revolution: Stop the Clock Time is on Your Side for a Younger, Stronger, Happier You | |
JP7069531B2 (ja) | ピロロキノリンキノン又はその塩と分岐鎖アミノ酸とを含むカプセル | |
WO2018066394A1 (ja) | 筋肉を柔軟にするための組成物 | |
Niewold | The effect of nutrition on stress and immunity | |
Lower et al. | High Nutritional value | |
Wu et al. | Effect of replacement of SDPP with yeast extracts in piglets on plasma amino acids and intestinal mucosa morphology. | |
Singh et al. | 19 Vitamins and Minerals: Roles and Plant Sources | |
JP2006282644A (ja) | 疲労回復剤 | |
RU2021138255A (ru) | Питательная смесь на основе mct для обеспечения полезных для здоровья эффектов у животных | |
WO2017014149A1 (ja) | 抗肥満用組成物 |